Invested in Odola Labs, a company engineering recombinant hemoglobin variants for shelf-stable synthetic blood, in an Early Stage VC round.
Biotechnology research and development unit specializing in synthetic blood substitute technologies
Biotechnology research and development unit specializing in synthetic blood substitute technologies. Addressing global blood shortage through next-generation synthetic hemoglobin variants.